X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Amgen & Eisai to participate in the immune modulation domain of REMAP-COVID, an adaptive clinical trial to test interventions for patients hospitalized with COVID-19. Amgen’s Apremilast & Eisai’s Eritoran to be evaluated across multiple international trial sites.
Lead Product(s): Apremilast,Eritoran,Hydrocortisone
Therapeutic Area: Infections and Infectious Diseases Product Name: Otezla
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
In this collaborative research, a non-clinical animal model of SARS-CoV-2 infection will be constructed. Additionally, TLR4 antagonist eritoran, discovered by Eisai, and an anti-FKN antibody E6011, KAN Research Institute, will be evaluated.
Lead Product(s): Eritoran
Therapeutic Area: Infections and Infectious Diseases Product Name: E5564
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 06, 2020
Details:
The trial will be conducted in the multi-hospital UPMC health system along with other medical centers in the United States. Additional global sites across the trial network, including Japan, will follow.
Lead Product(s): Eritoran
Therapeutic Area: Infections and Infectious Diseases Product Name: E5564
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Global Coalition for Adaptive Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 01, 2020
Details:
Eisai has resuscitated its once-jettisoned sepsis drug eritoran, otherwise known as E5564, for the treatment of COVID-19, planning to launch a global clinical trial as early as June.
Lead Product(s): Eritoran
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
